Objective: Grey matter (GM) atrophy occurs in all multiple sclerosis (MS) phenotypes. We investigated whether there is a spatiotemporal pattern of GM atrophy that is associated with faster disability accumulation in MS.
Introduction
The clinical course of multiple sclerosis (MS) is heterogeneous. Some patients experience relapses with recovery (relapsing-remitting [RR] MS), while others develop progressive disability either from the onset (primary-progressive [PP] MS), or after a period of relapses (secondary-progressive [SP] MS). RRMS patients account for approximately 90% of cases at onset 1 , whose majority later progress to SPMS. The pathogenic mechanisms driving accrual of disability are beginning to be elucidated 2 : neurodegeneration plays a crucial role in determining accrual of disability over time 3 .
Neurodegeneration is reflected in-vivo by reduced brain volume (or brain atrophy), which can be measured by MRI 3 . Over time, brain volume declines more rapidly in MS patients when compared with age-matched healthy controls (HCs) [3] [4] [5] [6] . Across MS phenotypes, SPMS shows the fastest annual rate of brain atrophy, which is estimated to be 0.6% (compared to about 0.2% in age-matched HCs) 5 . The role of brain atrophy in monitoring response to treatments in MS is evolving: whole brain atrophy has been recently used as primary outcome measure in Phase II clinical trials in SPMS 7, 8 . Whole brain atrophy is mainly driven by neuroaxonal loss in the GM 3 . GM volume loss is associated with long-term disability 9, 10 , and explains physical disability better than white matter 9, 11 and whole brain atrophy 5 . Some GM regions, such as the cingulate cortex and thalamus, are affected by volume loss more extensively than others 12, 13 , and the extent of their volume loss correlates with disability 13, 14 , and cognitive impairment 15 . Regional predilection for atrophy is not unique to MS; for example, hippocampal atrophy is more pronounced than the whole brain atrophy in the early phase of Alzheimer's disease 16 .
Although cross-sectional studies have previously shown patterns of regional atrophy in different types of MS 12, 17 , studies on longitudinal evolution of atrophy in different structures across MS phenotypes are scarce.
The overarching goal of our study was to investigate whether there is a spatiotemporal pattern of GM atrophy that is associated with faster disability accumulation in MS. In a large multi-centre cohort, which included all MS phenotypes and HCs, we tested the following hypotheses: (i) some GM regions show faster atrophy rate than others and their rate may differ between MS phenotypes; (ii) smaller baseline volumes of brain structures, reflecting a more extensive neurodegeneration, predict disability accrual; (iii) the rate of regional volume loss is associated with the rate of disability accumulation.
Methods

Participants
In this retrospective study we collected data from 7 European MS centres (MAGNIMS: www.magnims.eu) from 1,424 participants who have been studied between 1996 and 2016;
we included participants who fulfilled the following criteria: (1) a diagnosis of MS according to 2010 McDonald Criteria 18 or a clinically isolated syndrome (CIS) 19 ; (2) healthy controls (HCs) without history of neurological or psychiatric disorders; (3) at least two-MRI scans acquired with a minimal interval of 6 months with identical protocol, including highresolution T1-weighted MRI (allowing regional grey and white matter segmentation), and T2/Fluid Attenuated Inversion Recovery (FLAIR), sequences. Patients were scored on Expanded Disability Status Scale (EDSS) 20 . To increase the number of HCs scans, which were provided by 4 centres, we collected data from age-matched HCs from the Parkinson's MRI scans were taken under consent obtained from each subject independently in each centre. The final protocol for this study was reviewed and approved by the European MAGNIMS collaboration for analysis of pseudo-anonymised scans.
Image acquisition
We included scans from 13 different MRI protocols; all centres except one provided 3D-T1 weighted scans ( Supplementary Table 1 and Supplementary Table 2 show the MRI protocols).
Image analysis
We performed image analysis as follows:
1) Bias field correction
We used N4 bias field correction to correct for field inhomogeneity in T1-weighted scans using ANTs v2.10 21 .
2) Lesion filling
Lesion masks were manually delineated on PD/T2 images by different raters at each centre semi-automatically, except for 3 centres that used the same automatic lesion segmentation with LST toolbox (version 2.0.15) 22 .We calculated linear transformation matrices to register T2/FLAIR with the T1-weighted scan using FSL-FLIRT v5.0 23 . Then we applied these matrices to lesion masks to transfer them into the accompanying T1 subject-space. We used the FSL lesion filling method which uses a white matter mask calculated with FSL-FAST 24 to fill T1 hypo-intensities within normal-appearing whiter matter, so to reduce segmentation errors, as previously done [25] [26] [27] .
3) Symmetric within-subject registration
To avoid asymmetric registration and interpolation of longitudinal scans (e.g., toward the baseline scan), we constructed an unbiased subject-specific template that has "equal distance" from each time point using FreeSurfer version 5.3 [28] [29] [30] . We linearly transformed T1-weighted images to this symmetric space with the unbiased transformation matrix for each time point and used cubic B-spline interpolation to reduce interpolation artefacts. We manually checked the alignment of scans in the symmetric space.
4) Tissue segmentation
Next, in the symmetric space, we segmented T1 scans into the GM, white matter and cerebrospinal fluid with the Geodesic Information Flow (GIF) software (part of NifySeg, http://cmictig.cs.ucl.ac.uk/niftyweb/program.php?p=GIF) 31 , and parcellated each hemisphere into regions of interest according to the Neuromorphometric atlas 32 . GIF uses an atlas propagation and label fusion strategy to calculate the voxel probabilities of GM, white matter and CSF 31 ; this method has been previously used in MS and other neurodegenerative disorders 33, 34 . The template library had 95 MRI brain scans (HCs and patients with Alzheimer's disease) with neuroanatomic labels (http://www.neuromorphometrics.com/). This atlas, which is similar to Mindboggle atlas, was developed to improve the consistency and clarity of Desikan-Killiany protocol 32 .
To calculate brain masks and exclude segmentation errors outside of the brain we used
STEPS (Similarity and
Truth Estimation for Propagated Segmentations, http://cmictig.cs.ucl.ac.uk/niftyweb/program.php?p=BRAIN-STEPS) based on a template library of 682 hand-drawn brain masks 35, 36 . These maps were applied to each time point separately.
5) Regional volume calculation
We visually assessed the segmentations to assure the quality for statistical analysis. To calculate regional volumes, we summed the probability of the segmented tissue voxels (GM or white matter) in each parcellated region and multiplied the sum with the voxel volume.
We averaged values between left and right hemispheres. Next, we summarised the regional volumes according to Neuromorphometrics protocol by summing the volume of GM regions in the temporal, parietal, occipital, frontal lobes, cerebellum and deep GM (DGM) [thalamus, putamen, globus pallidus, caudate, and amygdala]. We also obtained the volume of the brainstem and of the cerebral white matter. Figure 1 shows the image analysis pipeline.
<……. Figure 1 …… >
Statistical analysis
Brain volumes at baseline and rates of volume changes over time
To investigate baseline volumes (intercept) and rates (slopes) of volume change by subject group and region, we used linear mixed-effects models with the volume at a given time as the response variable, and time and interactions with time as fixed-effect covariates 37 . This model estimates adjusted rate while allowing for nested correlation structures, such as time of visit within subject within scanner, by incorporating, in this example, subject and scanner random intercepts, and a random slope on time. The interaction terms with time (e.g., subject group X time), allows the estimation of rate differences across the interacting variable, in this example subject groups or clinical phenotypes. Including another interaction with time, such as gender X time, adjusts the rate for gender. In addition to time, the fixed-effect covariates were: scanner magnetic field, subject group, gender, age at baseline, total intracranial volume (sum of the volumes of GM, WM and CSF) at baseline; and the interactions of each of these with time. Disease duration was too highly correlated with age at baseline to give reliable estimation, and was omitted from the final models. To estimate the percentage changes per unit (year) increase in time, we log-transformed the volume 38 . We adjusted time to zero for those visits in which a patient converted from one phenotype to another (e.g., CIS to RRMS).
We performed post-hoc analyses to identify specific GM regions within the cerebral lobes and among the DGM nuclei that showed significant differences between MS phenotypes, as well as the default-mode network regions 39 .
To investigate whether there is an association between the rate of loss in specific regions and MS phenotypes, 3-way interactions were used, for example, clinical phenotype × region × time. We used R (version 3.2.2) and the NLME package 40, 41 .
For each model, we visually checked the heteroscedasticity (which is the unequal variance of a variable across the range of values of a second variable that predicts it) per group by plotting residuals against the fitted values.
We corrected for multiple comparisons accounting for the number of all the tests performed with the false-discovery rate method.
Effect of MRI protocols on imaging measures
To assess the effect of the MRI protocol on MRI measures (we took into account the protocols rather than the centres because some centres acquired more than one protocol with more than one scanner) we included it as a fixed-effect variable in a separate mixed-effect model, and calculated the average effect sizes for MRI protocols and MS phenotypes (i.e., disease effects) while fixing other variables.
Assessing associations between brain tissue volumes and disability accrual
For easier interpretation of clinical and imaging measures, we standardised volumes by subtracting the mean and dividing by the standard deviation (Z-score). We analysed CIS and relapse-onset patients together, because some patients had converted from CIS to RRMS, or from RRMS to SPMS. This allowed us to take advantage of a longer follow-up period. With similar mixed-effects models we investigated the following three questions: (1) Are the baseline volumes of the DGM, the temporal, frontal, parietal, occipital and cerebellar GM, brainstem, and white matter, and white matter lesion load associated with EDSS at baseline?
(2) Are changes in all these regional volumes and white matter lesion load associated with
EDSS changes over time? (3) Do baseline volumes of all these regions and white matter lesion at baseline predict time-to-EDSS progression (event=EDSS progression) during
follow-up? The EDSS-progression event was defined as 1.5 increase in EDSS, if the baseline EDSS was 0; one-point increase if EDSS was less than or equal to 6; and 0.5 increase if EDSS was more than 6 42 . We used a Cox-regression model to explore whether baseline volumes of these structures predicted time to event. We performed a post-hoc analysis using all GM regions to determine the most important predictors of time-to-EDSS-progression (as defined above) and confirm that the results of the DGM were not affected by the bias of merging a higher number of cortical regions into the main lobes. We performed FDR correction to adjust for multiple comparisons.
Additional analyses: software reliability and effects of disease modifying treatments
We carried out additional analyses to assess the reliability of brain volumes estimated with GIF software, FSL-FIRST, and SPM12, and effects of treatments on atrophy measures (see
Supplemental Material).
Results
The MRI scans of 1,417 subjects were analysed (scans of three subjects were excluded due to significant motion artefacts on visual inspection and four due to registration issues because of missing MRI header information); 1,214 patients (253 had CIS, 708 had RRMS, 128 had SPMS, and 125 had PPMS), and 203 were HCs. In total, we analysed 3,604 T1-weighted MRI. Average number of scans per subject was 2.54 (SD=1.04), with an average follow up of 2.41years (SD=1.97) for patients, and 1.83 (SD=1.77) years for HCs (see Table 1 for followup information per group). The total numbers of participants with 3 or more visits for each There was a significant difference in gender ratio between groups (p<0.001, see Table 1 Table 1 ).
<… … Table 1 … … >
Brain atrophy at baseline in MS and rates of volume changes over time
At baseline, all clinical phenotypes (CIS, RRMS, SPMS, and PPMS) had significantly smaller cortical GM and DGM volumes than HCs. SPMS showed the lowest cortical GM and DGM volumes, followed by PPMS, RRMS, CIS. All clinical phenotypes, but not CIS, had significantly reduced whole brain and white matter volumes when compared to HCs (see Similarly, the parietal GM showed a faster volume loss in SPMS (-1.24%) than CIS (-0.63%) (p<0.05) (Figure 2B and Supplementary Tables 3 and 4 ). No differences in rates of volume loss were seen in the frontal and occipital GM between clinical phenotypes. Overall, all the cortical GM regions, with the exception of the occipital cortex, showed a faster rate of atrophy in MS than HCs (Figure 2B and Supplementary Table 4 ).
The white matter did not show a significant rate of volume loss in HCs or any of the clinical phenotypes.
There was no heteroscedasticity in the plots of residuals against fitted values.
In the post-hoc analyses when looking at regions and clinical phenotypes we found that among the DGM nuclei, the putamen showed the fastest volume loss in PPMS (-2.6%).
Within the temporal lobe GM, the fastest volume loss was seen in the temporal pole (-1.47%) and posterior insula in SPMS (-1.19%). When looking at the parietal lobe GM, the precuneus showed the fastest atrophy rates in SPMS (-1.28%) (Figure 2C) . Whilst the fastest rate of atrophy was seen in DGM in SPMS, the temporal lobe GM showed the highest difference between SPMS and HCs (see Figure 2C ).
There was no significant effect of gender on rates of atrophy. There was no significant association between GM volumes and T2 (or FLAIR) lesion load.
<… … Figure 2 … … >
Regions showing the highest rate of loss
When we compared the rate of volume loss across different regions in all patients (CIS, RRMS, SPMS, and PPMS) together, the fastest decline (or lowest slope) was seen in the DGM (Supplementary Tables 3 and 4) . The rate of loss in the cortical GM regions was similar between lobes and to that of the cerebellum. The slowest rate of loss was seen in the brainstem.
Spatiotemporal pattern of GM volume loss in clinical phenotypes
Although SPMS showed the lowest baseline volumes of cortical GM and DGM, and the rate of the DGM volume loss was faster in SPMS, PPMS and RRMS than CIS and HCs, there was no significant association between the rate of loss in specific regions and clinical phenotypes, which suggests that all clinical phenotypes share a similar spatiotemporal pattern of GM loss.
Effect of MRI protocols on imaging measures
The average effects of MS phenotypes on brain volumes at baseline were higher than the protocol effect on the brain volumes (protocol effects: whole brain = 4.3%, cortical GM =5.1%, DGM = 8.5%, disease effects: whole brain = 4.8%, cortical GM =5.2%, DGM=13.7%). The average effects of MS phenotypes were higher than the effects of protocol on the rates of atrophy of the cortical GM and DGM (protocol effects: cortical GM = 0.14%, DGM = 0.21%, disease effects: cortical GM = 0.57%, DGM =0.53%), but not those of the whole brain (protocol effect = 0.51%, and disease effect = 0.38%).
Association between EDSS and GM loss
In Figure 3 illustrates the survival-curve for these analyses.
<… … Figure 3 … … >
In the post-hoc analyses, baseline thalamic volume had the highest predictive value of EDSSprogression during follow-up in both PPMS and the relapse-onset groups, by increasing the risk to a shorter time to EDSS worsening of 37% in relapse-onset MS and 40% in PPMS (Figure 4B and C) . In this analysis, the predictive value of the thalamus was followed by that of the hippocampus and angular gyrus in relapse-onset MS (Figure 4B) , and by that of the putamen, posterior insula and temporal pole in PPMS (Figure 4C) .
<… … Figure 4 … … >
There were no significant differences in the rates of loss in patients who were receiving disease-modifying drugs and those who were not (see Supplementary Text) . The analyses with GIF software, FSL-FIRST, and SPM12 confirmed the reliability of brain volumes estimates (see details in Supplementary Text).
Discussion
In this large multicentre study, we have shown that volume loss in DGM over time was faster than that seen in other brain regions across all clinical phenotypes, and DGM volume loss was the only GM region associated with disability accumulation. Additionally, we found that the smaller DGM volume at baseline was associated with increased risk of shorter time to EDSS progression, in agreement with previous studies that showed smaller DGM volume associated with higher disability 14, 15 . Interestingly, we found that atrophy rates of the GM of cortical lobes were the fastest in SPMS, and were faster in the temporal lobe in SPMS in comparison with RRMS and CIS and in the parietal lobe in SPMS in comparison with CIS.
However, no significant association between cortical regions and disability progression was detected. Overall, our findings suggest that the development of DGM atrophy may drive disability accumulation irrespective of clinical phenotypes, thereby becoming a useful outcome measure in neuroprotective clinical trials. Although the spatiotemporal pattern of atrophy remains similar across MS phenotypes, some cortical regions show accelerated atrophy in SPMS than RRMS and/or CIS. We now discuss these results in turn and in detail.
The pathological events that underpin DGM atrophy are not known, but this is generally interpreted as the result of neurodegeneration. Previous studies have shown that DGM atrophy is more severe in patients with progressive MS, longer disease duration and worse cognitive performance 14, 15, 45 . Our post-hoc analyses showed that the thalamus, which is the DGM's largest component, was a better predictor of future disability than other regions, and the rate of atrophy in the putamen was the highest across DGM nuclei. Previous studies, including those using advanced MRI, have found that thalamic damage at study entry was associated with higher disability [13] [14] [15] . DGM structures are extensively connected with cortical GM regions, and therefore DGM atrophy could be due to retrograde and anterograde neurodegeneration via tracts that connect GM areas. For example, the extent of cellular density loss in the thalamus, is associated with neurodegeneration in the remote (but connected) cortical regions, over and beyond the extent of atrophy explained by demyelination in connecting tracts 46 . There is also evidence of other neurodegenerative mechanisms in the DGM nuclei. For example, their higher load of iron than other regions can accumulate oxidised lipids which are associated with neurodegeneration 47 . In our healthy controls, the rate of DGM atrophy was faster than that in other regions, suggesting that it may be a hot spot for both age-and disease-related atrophy in the human brain, although a methodological issue, related to its more uniform structure than other brain regions, cannot be excluded. Nevertheless, the DGM volume holds strong promise as a marker of disease progression with the potential to respond to neuroprotective treatments that target neurodegeneration in MS.
Interestingly, the temporal lobe showed a significant acceleration in SPMS when compared to both RRMS and CIS. Similarly, the parietal lobe GM showed a significant acceleration of atrophy in SPMS in comparison with CIS. Our post-hoc analysis showed that the temporal pole and insula were the most affected structures in the temporal GM. Pathological studies have demonstrated an increase in the rate of neurodegeneration, especially in the temporal regions, during progressive stages of MS in comparison with RRMS and CIS 49, 50 . Overall, a global pathological process in MS 51 , may become more pronounced in certain regions, such as the temporal GM, because of other mechanisms, such as static exposure to CSF (the insula in the temporal lobe) or hypoxia in watershed areas (some DGM nuclei such as the pallidum).
For example, meningeal inflammation and cortical demyelination, which may play a role in cortical atrophy, preferentially affect deep sulci, such as the insula, where there is more exposure to static inflammatory cytokines 2, 49, 52 . Our findings also suggest that regions with more connections may be vulnerable to atrophy. For example, among the parietal cortical regions, the precuneus, a core part of an important functional brain network (default mode network), showed the fastest atrophy rates in SPMS 39 . Thus, acceleration of atrophy during SPMS may be explained by cortical network collapse with advancing of degeneration from initial injury sites (focal lesions in the white matter or initial DGM degeneration) to interconnected neocortical systems 53 . We found that MS phenotypes shared a common spatiotemporal pattern of volume loss (no significant 3-way interaction of time × region × phenotype). This shows, in line with previous studies, that the difference in pathology of progressive MS is only quantitative rather than qualitative in comparison with RRMS 2,55 .
Cortical GM atrophy was seen at study entry across clinical phenotypes, even in CIS, when compared with HCs, and was the greatest in progressive MS, in agreement with earlier studies 17, 56 .Our findings of faster whole brain atrophy in SPMS, PPMS, RRMS than CIS, who in turn, showed higher cortical atrophy than HCs, are similar to previous studies on longitudinal whole brain atrophy 5,57,58 , regional atrophy 17,59-61 , and pathology of MS phenotypes 2, 49 . Our study confirms our previous findings that relationships between whole brain atrophy and clinical changes are weak or absent 5 , and shows DGM atrophy as a stronger marker of clinical disability. Although the GM volumes of cortical lobes could not predict future EDSS progression, the more detailed post-hoc analyses showed that regional volumes, such those of the hippocampus and the angular gyrus, were associated with future EDSS progression. These regions are highly connected to other regions, and especially the angular gyrus (like the precuneus) acts as a hub in the default mode network, which could make it vulnerable to atrophy, as explained above 39 .
This study was not designed to assess the effect of treatment on atrophy rates, but does study atrophy while adjusting for possible confounding effects. The rates of atrophy in all clinical phenotypes were similar in people who were receiving disease-modifying treatments to those who were not. Even though we could not ascertain the duration of treatments due to retrospective nature of this study, the majority (90%) of patients on disease modifying treatments, were receiving first-line injectable drugs (interferon or glatiramer acetate) before study entry. The effects of these drugs on brain atrophy are modest at best 62, 63 . Therefore, drug effects are unlikely to be confounders of our analysis.
One strength of our study is that we included a large number of patients, who underwent the same protocol on the same MRI scanner over time at single sites. However, different MRI protocols could have an effect on atrophy measures and is a limitation of our study 64, 65 . We therefore used a hierarchical statistical design based on scanner. Our study was powerful enough because the effects of clinical phenotype on the regional rates of atrophy were higher than the effects of between-centre variation.
We chose GIF software to segment and parcellate the brain 31 because it allowed inclusion of 2D MRI data (which we had for one centre), and did not require any manual editing, unlike
Freesurfer, which would have been unfeasible for such large number of scans. Our reliability analysis showed excellent agreement between GIF-derived DGM volume and that obtained using FSL-FIRST, and between GIF-derived cortical volumes and those obtained using SPM12, respectively. Therefore, we chose to present the results obtained with GIF because it allowed us to rely on only one method to segment DGM and cortical GM, and estimate TIV.
We used TIV to adjust for variations in head size, rather than the skull-size, so that a more reliable estimate of head size is obtained, irrespectively of the field-of-view, the choice of the inferior cut-off of the brain for the analysis, and demographic factors (e.g., age, or weight) 70 .
With regard to the statistical methods, we used mixed-effects models to calculate atrophy rates 41 , which naturally accommodated multiple (3 or more) time-points with varying intervals between follow-ups, and patients who convert from one phenotype to another (e.g., CIS to RRMS). These two issues are cumbersome to address with methods that rely on pairwise comparisons (e.g., SIENA, BSI) and suffer from higher variance in brain atrophy estimates as the interval between two scans increases 66, 67 . Mixed-effects modelling, instead, estimates a variance component to eliminate implausible inconsistencies 68, 69 . Based on our experience and the results of this study, we recommend the acquisition of high-resolution 3D-T1 images (isotropic 1mm 3 ). Several methods can calculate DGM volumes, such as FSL-FIRST, and GIF. We recommend the use of the GIF software when it is desirable to use the same method to segment both the cortex and DGM.
There were also limitations in this study. The majority of centres did not provide MRI scans of HCs, however, we included a large number of HCs including those from an external initiative (PPMI). Our findings of volume changes in HCs were consistent with the literature.
Meta-analyses have shown, in individuals less than 70 years of age, rate of whole brain loss ranges from 0 to -0.5 (our study = -0.04), GM loss ranges from 0 to -0.5% per year (cortical GM in our study = -0.34%) 71 , and the subcortical structures may show loss of up to -1.12%
(DGM in our study = -0.94) 72 . comparison between brain regions, the absolute value of these coefficients must be interpreted with caution, because the EDSS does not have a uniform linear interpretation.
Since this was a retrospective study, the duration of treatments before entry to the study could not be ascertained for all participants. Disease modifying drugs may have lasting effects, for example they may slow the accrual of disability after a decade 63, 73 . Moreover, MRI sequences sensitive to cortical lesions were not available, and the effects of cortical lesions on atrophy measures remain unknown.
In conclusion, the DGM atrophy showed the most rapid development over time-extending previous cross-sectional studies that showed a relationship between DGM atrophy and disabilitywas most closely associated with disability accumulation and predicted the time to EDSS worsening. In phase II trials of neuroprotective medications in MS, DGM atrophy measures may therefore have greater potential to show treatment effects than other regional GM or whole brain measures. There was a disconnect between DGM atrophy and cortical atrophy rates. The temporal and parietal cortices showed a faster rate of atrophy in SPMS than RRMS and/or CIS, whilst DGM showed a faster rater of atrophy in SPMS than CIS only, suggesting that neurodegeneration in GM regions may proceed at a different rate which should be taken into account in the design of clinical trials. Baseline values (A) and rates (B, and C) were adjusted in a single mixed-effects hierarchical model including age, gender, total intracranial volume at baseline, scanner magnetic field, and their interactions with time as the fixed-effects. Centre, subject and visits were nested (hierarchical) random-effects.
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